PMID- 29544697
OWN - NLM
STAT- MEDLINE
DCOM- 20181106
LR  - 20211204
IS  - 1873-2496 (Electronic)
IS  - 1078-1439 (Linking)
VI  - 36
IP  - 6
DP  - 2018 Jun
TI  - The expression of p-mTOR and COUP-TFII correlates with increased 
      lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma.
PG  - 311.e27-311.e35
LID - S1078-1439(18)30047-4 [pii]
LID - 10.1016/j.urolonc.2018.02.007 [doi]
AB  - BACKGROUND: Mammalian target of rapamycin (mTOR) is a central regulator of major 
      cellular processes such as growth and proliferation. Deregulated mTOR signaling 
      is implicated in a wide spectrum of human malignancies including prostate cancer. 
      The aim of this study is to address the role of phosphorylated mTOR (p-mTOR) in 
      prostate adenocarcinoma-induced lymphangiogenesis and lymph node metastasis as 
      well as to investigate its relationship with chicken ovalbumin upstream promoter 
      transcriptional factor 2 (COUP-TFII) and the vascular endothelial growth factors 
      A/C (VEGF A/C). METHODS: We analyzed 92 paraffin embedded specimens from patients 
      with prostate cancer who underwent radical prostatectomy with pelvic lymph node 
      (LN) dissection. Twenty-four of these men were pathologically assessed to have 
      regional LN metastasis (pN1 group) and 68 with negative lymph nodes (pN0 group). 
      Lymph vessel density was measured using anti-D2-40 and anti-LYVE-1 antibodies. 
      The expression of p-mTOR, COUP-TFII, and VEGF A/C was also evaluated by 
      immunohistochemistry. RESULTS: Specimens from pN1 group exhibited higher 
      cytoplasmic p-mTOR expression compared to pN0 specimens. Mean vessel densities 
      assessed by COUP-TFII and D2-40 were increased in pN1 tumors and positively 
      associated with higher p-mTOR expression. Interestingly, increased expression of 
      p-mTOR was positively associated with COUP-TFII expression in cancer cells and 
      elevated immunoreactivity for both VEGF A and C, which in turn exhibited higher 
      expression in pN1 group. CONCLUSIONS: Our findings suggest that increased p-mTOR 
      and COUP-TFII expression are implicated in human prostate adenocarcinoma-induced 
      lymphangiogenesis and LN metastasis.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Lilis, Ioannis
AU  - Lilis I
AD  - Department of Anatomy, Faculty of Medicine, University of Patras, Rio, Achaia, 
      Greece. Electronic address: ioannislilis@upatras.gr.
FAU - Giopanou, Ioanna
AU  - Giopanou I
AD  - Department of Anatomy, Faculty of Medicine, University of Patras, Rio, Achaia, 
      Greece. Electronic address: giopanou@upatras.gr.
FAU - Papadaki, Helen
AU  - Papadaki H
AD  - Department of Anatomy, Faculty of Medicine, University of Patras, Rio, Achaia, 
      Greece.
FAU - Gyftopoulos, Kostis
AU  - Gyftopoulos K
AD  - Department of Anatomy, Faculty of Medicine, University of Patras, Rio, Achaia, 
      Greece.
LA  - eng
PT  - Journal Article
DEP - 20180312
PL  - United States
TA  - Urol Oncol
JT  - Urologic oncology
JID - 9805460
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (COUP Transcription Factor II)
RN  - 0 (VEGFA protein, human)
RN  - 0 (VEGFC protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factor C)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adenocarcinoma/metabolism/*secondary/surgery
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - COUP Transcription Factor II/*metabolism
MH  - Follow-Up Studies
MH  - Humans
MH  - *Lymphangiogenesis
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Phosphorylation
MH  - Prognosis
MH  - Prostatectomy
MH  - Prostatic Neoplasms/metabolism/*pathology/surgery
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - Vascular Endothelial Growth Factor C/metabolism
OTO - NOTNLM
OT  - Adenocarcinoma
OT  - Metastasis
OT  - NR2F2
OT  - Prostate
OT  - mTOR
EDAT- 2018/03/17 06:00
MHDA- 2018/11/07 06:00
CRDT- 2018/03/17 06:00
PHST- 2017/06/22 00:00 [received]
PHST- 2017/11/23 00:00 [revised]
PHST- 2018/02/14 00:00 [accepted]
PHST- 2018/03/17 06:00 [pubmed]
PHST- 2018/11/07 06:00 [medline]
PHST- 2018/03/17 06:00 [entrez]
AID - S1078-1439(18)30047-4 [pii]
AID - 10.1016/j.urolonc.2018.02.007 [doi]
PST - ppublish
SO  - Urol Oncol. 2018 Jun;36(6):311.e27-311.e35. doi: 10.1016/j.urolonc.2018.02.007. 
      Epub 2018 Mar 12.